Target intelligence / Profile preview

Cytochrome P450 superfamily (CYP450)

Target
CYP450
Molecular classification
Enzyme, Oxidoreductase, Heme protein, Monooxygenase
01

Overview

The Cytochrome P450 (CYP450) superfamily is a large and diverse group of heme-containing enzymes that play a central role in the oxidative metabolism of a wide range of endogenous and exogenous compounds (Guengerich, 2008). While major isoforms such as CYP3A4 and CYP2D6 are well-known for their role in drug clearance, the category of "Other CYP450 enzymes" encompasses numerous isoforms like CYP1A2, CYP2C9, CYP2C19, and CYP2E1, which are vital for the biotransformation of specific drugs and environmental toxins (Lynch & Price, 2007). These enzymes are primarily localized in the liver but are also found in extrahepatic tissues, where they facilitate the conversion of lipophilic substances into water-soluble metabolites (UniProt, 2024). Beyond drug metabolism, many CYP enzymes are involved in critical physiological processes, including the synthesis of steroid hormones, cholesterol, and vitamin D (NIH, 2023). In the context of pharmacology, these enzymes are significant due to their high degree of genetic polymorphism and their susceptibility to inhibition or induction by other drugs, which can lead to profound drug-drug interactions (FDA, 2020). Understanding the activity and variability of these enzymes is essential for personalized medicine and for minimizing the risk of adverse drug reactions in clinical settings (StatPearls, 2023).

Other names
CYPP450Heme-thiolate monooxygenasesMicrosomal hydroxylasesMixed-function oxidases
02

Mechanism of action

Drugs interact with these enzymes as substrates for oxidative biotransformation, or as inhibitors and inducers that modulate enzymatic activity and expression levels (Guengerich, 2008).

03

Biological functions

Xenobiotic metabolismSteroidogenesisFatty acid oxidationVitamin D metabolismBile acid synthesis
04

Disease associations

Drug-drug interactionsCancerMetabolic disordersToxicityCongenital adrenal hyperplasia
05

Safety considerations

Clinically significant drug-drug interactionsHepatotoxicityTherapeutic failure due to rapid metabolismBioactivation of toxins or pro-carcinogens
06

Interacting drugs

Warfarin

7 more in the full profile.

07

Biomarkers

CYP2C19 genotypeCYP2C9 genotypeCaffeine metabolic ratio (for CYP1A2 activity)Plasma drug concentration monitoring

Beyond the preview

Go deeper on Cytochrome P450 superfamily (CYP450).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 superfamily (CYP450).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call